Ifosfamide
As of the edition of 20 October 2026, Ifosfamide is a small molecule: marketed, first approved in 1979 (CH).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1999
- Kind
- Small molecule
- Brand name
- Ifex
- First approved
- 11 September 1979 (CH)
- Approvals on record
- 10 in 6 regions
- Holder of the most recent approval
- Baxter Healthcare; 3 holders in all
- Registered trials
- 360, 44 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Urinary and reproductive; Pregnancy and women's health; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 25 | 11 | 5 | 2 |
| Phase 1 | 37 | 20 | 5 | 9 |
| Phase 2 | 203 | 111 | 33 | 26 |
| Phase 3 | 85 | 44 | 18 | 7 |
| Phase 4 | 10 | 4 | 2 | 0 |
| All trials | 360 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Baxter Healthcare | Applicant and Acquired holder | 1979 to now |
| Bristol Myers Squibb | Applicant | 1988 to now |
| Shionogi | Applicant |